Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Circulating tumor cells are predictive of outcome for breast cancer patients
February 16th, 2006
Immunicon Corp. (IMMC) reviewed key scientific and technical achievements in 2005. Leon Terstappen, MD, PhD, Immunicon's senior VP of research and development and chief scientific officer, led the discussion. "We continued to add to our substantial body of scientific and clinical information in 2005 which will support product adoption and the growth of product sales for Immunicon," commented Byron D. Hewett, Immunicon's president and CEO. "Among the most notable accomplishments were the presentation of our additional clinical data in metastatic breast cancer at the June 2005 American Society of Clinical Oncology's annual meeting (ASCO) and the...
Source: Women's Health Weekly (2006-02-16)
|
